TY - JOUR
T1 - LocoMMotion
T2 - a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
AU - Mateos, Maria Victoria
AU - Weisel, Katja
AU - De Stefano, Valerio
AU - Goldschmidt, Hartmut
AU - Delforge, Michel
AU - Mohty, Mohamad
AU - Cavo, Michele
AU - Vij, Ravi
AU - Lindsey-Hill, Joanne
AU - Dytfeld, Dominik
AU - Angelucci, Emanuele
AU - Perrot, Aurore
AU - Benjamin, Reuben
AU - van de Donk, Niels W.C.J.
AU - Ocio, Enrique M.
AU - Scheid, Christof
AU - Gay, Francesca
AU - Roeloffzen, Wilfried
AU - Rodriguez-Otero, Paula
AU - Broijl, Annemiek
AU - Potamianou, Anna
AU - Sakabedoyan, Caline
AU - Semerjian, Maria
AU - Keim, Sofia
AU - Strulev, Vadim
AU - Schecter, Jordan M.
AU - Vogel, Martin
AU - Wapenaar, Robert
AU - Nesheiwat, Tonia
AU - San-Miguel, Jesus
AU - Sonneveld, Pieter
AU - Einsele, Hermann
AU - Moreau, Philippe
N1 - Funding Information: This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc. Medical writing support was provided by Julie Nowicki, PhD, of Eloquent Scientific Solutions, and funded by Janssen Global Services, LLC.
Publisher Copyright: © 2022, The Author(s).
PY - 2022/5
Y1 - 2022/5
N2 - Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life standard of care (SOC) in triple-class exposed (received at least a PI, IMiD, and anti-CD38 mAb) patients with relapsed/refractory MM (RRMM). Patients (N = 248; ECOG performance status of 0–1, ≥3 prior lines of therapy or double refractory to a PI and IMiD) were treated with median 4.0 (range, 1–20) cycles of SOC therapy. Overall response rate was 29.8% (95% CI: 24.2–36.0). Median progression-free survival (PFS) and median overall survival (OS) were 4.6 (95% CI: 3.9–5.6) and 12.4 months (95% CI: 10.3–NE). Treatment-emergent adverse events (TEAEs) were reported in 83.5% of patients (52.8% grade 3/4). Altogether, 107 deaths occurred, due to progressive disease (n = 74), TEAEs (n = 19), and other reasons (n = 14). The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action.
AB - Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life standard of care (SOC) in triple-class exposed (received at least a PI, IMiD, and anti-CD38 mAb) patients with relapsed/refractory MM (RRMM). Patients (N = 248; ECOG performance status of 0–1, ≥3 prior lines of therapy or double refractory to a PI and IMiD) were treated with median 4.0 (range, 1–20) cycles of SOC therapy. Overall response rate was 29.8% (95% CI: 24.2–36.0). Median progression-free survival (PFS) and median overall survival (OS) were 4.6 (95% CI: 3.9–5.6) and 12.4 months (95% CI: 10.3–NE). Treatment-emergent adverse events (TEAEs) were reported in 83.5% of patients (52.8% grade 3/4). Altogether, 107 deaths occurred, due to progressive disease (n = 74), TEAEs (n = 19), and other reasons (n = 14). The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action.
UR - http://www.scopus.com/inward/record.url?scp=85127467669&partnerID=8YFLogxK
U2 - 10.1038/s41375-022-01531-2
DO - 10.1038/s41375-022-01531-2
M3 - Article
C2 - 35332278
AN - SCOPUS:85127467669
SN - 0887-6924
VL - 36
SP - 1371
EP - 1376
JO - Leukemia
JF - Leukemia
IS - 5
ER -
